Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
Mon Nov 05 00:00:00 GMT-04:00 2018
EMA Validates and Grants Accelerated Assessment of Marketing Authorization Application for Daiichi ...
PDF (245 KB)
Thu Nov 01 00:00:00 GMT-04:00 2018
Daiichi Sankyo to Present Data from AML Franchise Including FLT3 Inhibitor Quizartinib at ASH Annua ...
PDF (231 KB)
Thu Oct 25 00:00:00 GMT-04:00 2018
Daiichi Sankyo Announces Clinical Research Collaboration with Merck KGaA, Darmstadt, Germany and Pf ...
PDF (182 KB)
Tue Oct 23 00:00:00 GMT-04:00 2018
Daiichi Sankyo, Inc. Publishes Second Edition of Pain Trends Report
PDF (211 KB)
Sun Oct 21 00:00:00 GMT-04:00 2018
Daiichi Sankyo Presents Updated Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with ...
PDF (193 KB)
Thu Oct 18 00:00:00 GMT-04:00 2018
Daiichi Sankyo Initiates Phase 1 Study of AXL Inhibitor DS-1205 in Patients with EGFR-Mutated Metas ...
PDF (186 KB)
Wed Oct 17 00:00:00 GMT-04:00 2018
Daiichi Sankyo Submits Application in Japan for FLT3 Inhibitor Quizartinib for Treatment of Patient ...
PDF (286 KB)
Wed Oct 03 00:00:00 GMT-04:00 2018
Japan MHLW Grants Orphan Drug Designation to Axicabtagene Ciloleucel for Treatment of Certain Types ...
PDF (101 KB)
Tue Sep 25 00:00:00 GMT-04:00 2018
Daiichi Sankyo Initiates Two Phase 3 Trials of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients ...
PDF (205 KB)
Mon Sep 24 00:00:00 GMT-04:00 2018
Daiichi Sankyo Presents Updated Results for [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients wit ...
PDF (269 KB)
Showing 1 - 10 of 42 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...